Pseudomembranous colitis: an update.

作者: Harpreet S Brar , Christina M Surawicz

DOI: 10.1155/2000/324025

关键词: Clostridium difficile toxin BSaccharomyces boulardiiClostridium difficileGastroenterologyPseudomembranous colitisVancomycinInternal medicineClostridium difficile toxin ADiarrheaMicrobiologyMetronidazoleMedicine

摘要: Clostridium difficile is the most common nosocomial infection of gastrointestinal tract. Most cases are associated with antibiotic therapy that alters fecal flora, allowing overgrowth C production its toxins. Diagnosis made by detection organism or toxin in stools. A variety different tests can be used, but none perfect. stool culture positive someone without diarrhea, ie, a carrier. While cytotoxin gold standard, it expensive, and there delay before results available. Thus, many laboratories use enzyme-linked immunoassay to detect because they more rapid screen. Depending on specific test A, B occasionally both. Sensitivity specificity rates vary. First line for disease should metronidazole 250 mg qid 10 days. Vancomycin reserved severe where has failed cannot tolerated contraindicated. Recurrent particularly vexing clinical problem. biotherapeutic approaches have been used. Retreatment antibiotics almost always necessary. In addition, nonpathogenic yeast Saccharomyces boulardii showed benefit as an adjunct preventing further recurrences.

参考文章(44)
S. Cronberg, B. Castor, A. Thorén, Fusidic acid for the treatment of antibiotic-associated colitis induced by clostridium difficile Infection. ,vol. 12, pp. 276- 279 ,(1984) , 10.1007/BF01645961
Daniel F. Sahm, Stephen B. Hanauer, Janet Todorczuk, Bret A. Lashner, Clostridium difficile culture-positive toxin-negative diarrhea. The American Journal of Gastroenterology. ,vol. 81, pp. 940- 943 ,(1986) , 10.1111/J.1572-0241.1986.TB01362.X
K. Tsimidis, A. E. Simor, Evaluation of an enzyme immunoassay for detection ofClostridium difficile toxin A European Journal of Clinical Microbiology & Infectious Diseases. ,vol. 11, pp. 563- 564 ,(1992) , 10.1007/BF01960819
Marilou Corpuz, C. S. Pitchumoni, Harish Grover, Ravi Ramaswamy, Peter Daniels, Prognostic criteria in Clostridium difficile colitis. The American Journal of Gastroenterology. ,vol. 91, pp. 460- 464 ,(1996)
Charalabos Pothoulakis, Ciaran P. Kelly, Manher A. Joshi, Ning Gao, Connor J. O'Keane, Ignazio Castagliuolo, J.Thomas Lamont, Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. ,vol. 104, pp. 1108- 1115 ,(1993) , 10.1016/0016-5085(93)90280-P
D M Lyerly, T D Wilkins, Commercial latex test for Clostridium difficile toxin A does not detect toxin A. Journal of Clinical Microbiology. ,vol. 23, pp. 622- 623 ,(1986) , 10.1128/JCM.23.3.622-623.1986
Graeme P. Young, Peter B. Ward, Noel Bayley, David Gordon, Geoff Higgins, Joseph A. Trapani, Malcolm I. McDonald, Justin Labrooy, Robert Hecker, Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology. ,vol. 89, pp. 1038- 1045 ,(1985) , 10.1016/0016-5085(85)90206-9
R. Alonso, C. Muñoz, T. Peláez, E. Cercenado, M. Rodríguez-Creixems, E. Bouza, Rapid detection of toxigenic Clostridium difficile strains by a nested PCR of the toxin B gene. Clinical Microbiology and Infection. ,vol. 3, pp. 145- 147 ,(1997) , 10.1111/J.1469-0691.1997.TB00271.X
C S Merz, C Kramer, M Forman, L Gluck, K Mills, K Senft, I Steiman, N Wallace, P Charache, Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens. Journal of Clinical Microbiology. ,vol. 32, pp. 1142- 1147 ,(1994) , 10.1128/JCM.32.5.1142-1147.1994
P C De Girolami, P A Hanff, K Eichelberger, L Longhi, H Teresa, J Pratt, A Cheng, J M Letourneau, G M Thorne, Multicenter evaluation of a new enzyme immunoassay for detection of Clostridium difficile enterotoxin A. Journal of Clinical Microbiology. ,vol. 30, pp. 1085- 1088 ,(1992) , 10.1128/JCM.30.5.1085-1088.1992